Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions
Z Megyesfalvi, CM Gay, H Popper… - CA: a cancer journal …, 2023 - Wiley Online Library
Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity.
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …
Small-cell lung cancer
CM Rudin, E Brambilla, C Faivre-Finn… - Nature Reviews Disease …, 2021 - nature.com
Small-cell lung cancer (SCLC) represents about 15% of all lung cancers and is marked by
an exceptionally high proliferative rate, strong predilection for early metastasis and poor …
an exceptionally high proliferative rate, strong predilection for early metastasis and poor …
[HTML][HTML] Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer
Small cell lung cancer (SCLC) is an aggressive malignancy that includes subtypes defined
by differential expression of ASCL1, NEUROD1, and POU2F3 (SCLC-A,-N, and-P …
by differential expression of ASCL1, NEUROD1, and POU2F3 (SCLC-A,-N, and-P …
[HTML][HTML] SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization
MK Baine, MS Hsieh, WV Lai, JV Egger… - Journal of Thoracic …, 2020 - Elsevier
Introduction Recent studies have identified subtypes of small cell lung carcinoma (SCLC)
defined by the RNA expression of ASCL1, NEUROD1, POU2F3, and YAP1 transcriptional …
defined by the RNA expression of ASCL1, NEUROD1, POU2F3, and YAP1 transcriptional …
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
Small cell lung cancer (SCLC) is an exceptionally lethal malignancy for which more effective
therapies are urgently needed. Several lines of evidence, from SCLC primary human …
therapies are urgently needed. Several lines of evidence, from SCLC primary human …
[HTML][HTML] cfDNA methylome profiling for detection and subtyping of small cell lung cancers
Small cell lung cancer (SCLC) is characterized by morphologic, epigenetic and
transcriptomic heterogeneity. Subtypes based upon predominant transcription factor …
transcriptomic heterogeneity. Subtypes based upon predominant transcription factor …
[HTML][HTML] MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate
Small cell lung cancer (SCLC) is a neuroendocrine tumor treated clinically as a single
disease with poor outcomes. Distinct SCLC molecular subtypes have been defined based …
disease with poor outcomes. Distinct SCLC molecular subtypes have been defined based …
Small-cell lung cancer: what we know, what we need to know and the path forward
Small-cell lung cancer (SCLC) is a deadly tumour accounting for approximately 15% of lung
cancers and is pathologically, molecularly, biologically and clinically very different from other …
cancers and is pathologically, molecularly, biologically and clinically very different from other …
Immunotherapeutic approaches for small-cell lung cancer
Immune-checkpoint inhibitors (ICIs) are approved in the first-line and third-line settings for
patients with extensive-stage or relapsed small-cell lung cancer (SCLC), respectively. In the …
patients with extensive-stage or relapsed small-cell lung cancer (SCLC), respectively. In the …
[HTML][HTML] Senescence-induced vascular remodeling creates therapeutic vulnerabilities in pancreas cancer
KRAS mutant pancreatic ductal adenocarcinoma (PDAC) is characterized by a desmoplastic
response that promotes hypovascularity, immunosuppression, and resistance to chemo-and …
response that promotes hypovascularity, immunosuppression, and resistance to chemo-and …